{
  "docId": "019dd923-5e88-73ef-bd5c-f812573a947a",
  "docSlug": "eea7524c557036f4",
  "documentTitle": "2020 Air Street Capital The State of AI Report 2020",
  "authorId": "AirStreetCapital",
  "authorName": "Air Street Capital",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "vc_research",
  "sourceTypeLabel": "VC research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 84,
  "pageCount": 177,
  "prevPage": 83,
  "nextPage": 85,
  "slideType": "case_study",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a simple timeline structure to demonstrate the validation of AI in pharma.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "logo_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5c-f812573a947a/84",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5c-f812573a947a",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5c-f812573a947a.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5c-f812573a947a#slide-84",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "29 months after signing a €250M deal to evaluate over one thousand combinations of immunological drug targets for potential synergistic effects with bispecific small molecules, Exscientia discovers a novel, first-in-class small molecule that Sanofi will now progress.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-47c5-73ac-aa67-c8aa60b12b69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c2031e0-6207-4794-80d9-80a7297dc285",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.18,
        "y": 0.4
      },
      "kind": "list",
      "text": "MAY 9, 2017: Exscientia announces EUR250 million collaboration for a multiple-product development and licence option agreement with Sanofi",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "831b446b-67cd-426e-aa88-5817161e76cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.55,
        "y": 0.4
      },
      "kind": "list",
      "text": "AUGUST 5, 2019: Sanofi Exercises option on Exscientia-designed bispecific small molecule for treatment of immunological conditions",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "987619ce-6338-4a11-bdc7-4f3ae0f2e502",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Deal value: €250M",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-47c5-73ac-aa67-cdea7a231564",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "29 months after signing a €250M deal to evaluate over one thousand combinations of immunological drug targets for potential synergistic effects with bispecific small molecules, Exscientia discovers a novel, first-in-class small molecule that Sanofi will now progress.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c488077b-7db6-4cae-a0bc-084adbde72b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "title",
      "text": "Emerging evidence that large pharma is validating AI-first therapeutic discovery outputs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab73f648-49c6-4fa8-b626-fac23892a31d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Concrete Language",
      "slug": "concrete-language",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "019dd95a-0fd5-7148-8ecf-6723d58f387f",
      "evidence": "EUR250M deal, 29 months timeline specific.",
      "confidence": 75
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 129,
      "from": 10,
      "beatId": "019dd95a-0682-776c-8e34-ed2a8f38a754",
      "arcName": "The Triple Take",
      "arcSlug": "triple-take",
      "beatName": "The Facts (What)",
      "beatSlug": "triple-take-the-facts-what",
      "evidence": "Research, Talent, Industry sections inventory what happened in AI in 2020.",
      "position": 1,
      "confidence": 60,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    },
    {
      "to": 129,
      "from": 10,
      "beatId": "019dd95a-0682-776c-8e34-fc384f439bba",
      "arcName": "The Mountain",
      "arcSlug": "mountain",
      "beatName": "Rising Action",
      "beatSlug": "mountain-rising-action",
      "evidence": "Research, Talent and Industry sections build momentum of AI progress.",
      "position": 2,
      "confidence": 40,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 89,
      "from": 83,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "019dd95a-07fe-70ce-8d3d-0f7fddb1083f",
      "evidence": "Phase 1 trial, EUR250M Exscientia deal, mega rounds, MELLODDY, LabGenius.",
      "position": 10,
      "objective": "Show pharma validating AI-first drug discovery",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 75,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}